Fluvoxamine and COVID-19: Here’s How Fluvoxamine Might Help Prevent COVID-19 Infections From Getting Worse
Developed 40 years ago as an antidepressant, fluvoxamine—sometimes known as Luvox—has been used mainly to treat obsessive-compulsive disorder (OCD), per the National Alliance on Mental Illness (NAMI). But now, researchers are taking a closer look at how the medication could be an important treatment to prevent patients who test positive for COVID-19 from getting seriously ill with the infection.
In a new interview with 60 Minutes, Angela Reiersen, MD, a child psychiatrist at Washington University in St. Louis—and co-author of a November 2020 study published in the Journal of the American Medical Association (JAMA) regarding the use of fluvoxamine in COVID-19 patients—explained that she first got the idea that the drug could potentially treat COVID-19 after seeing research that fluvoxamine prevented sepsis in mice.
Fluvoxamine is in pole position as an accessible early treatment against Covid-19.— Covid19Crusher (@Covid19Crusher) April 21, 2021
The remarkable man behind its discovery has entered the world of drug approval with staunch pragmatism and faultless judgement..
but it is not going according to plan.https://t.co/M13y5FkHYB